InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Neumora Therapeutics, Inc.

NMRA Clue Score21
United States Fiscal year ends December CIK 0001885522 Results filed 14 Aug 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

16
Insider
Date
Role
Action
Shares
Price
Amount
Michael Lee Milligan
17 Feb 2026
See Remarks
Sold on a plan
1,436
$3.57
$5.12K
Daljit Singh Aurora
11 Nov 2025
See Remarks
Sold on a plan indirect
114,703
$2.68
$307.03K
Joshua Pinto
18 Feb 2025
President
Sold on a plan
8,048
$1.67
$13.48K
Robert A. Lenz
18 Feb 2025
Head of R&D
Sold on a plan
5,614
$1.67
$9.38K
Daljit Singh Aurora
18 Feb 2025
Chief Strategy Officer
Sold on a plan
8,565
$1.68
$14.35K
Michael Lee Milligan
18 Feb 2025
See Remarks
Sold on a plan
1,978
$1.69
$3.35K
Paul L Berns
18 Feb 2025
See Remarks
Sold on a plan
13,871
$1.69
$23.47K
Robert A. Lenz
10 Oct 2024
Head of R&D
Sold on a plan
8,260
$15.09
$124.60K
Robert A. Lenz
9 Oct 2024
Head of R&D
Sold on a plan
5,563
$15.01
$83.51K
Robert A. Lenz
18 Sep 2024
Head of R&D
Sold on a plan
10,676
$12.09
$129.09K
Robert A. Lenz
17 Sep 2024
Head of R&D
Sold on a plan
30,788
$11.81
$363.74K
Robert A. Lenz
12 Sep 2024
Head of R&D
Sold on a plan
32,948
$11.43
$376.66K
Joshua Pinto
27 Aug 2024
Chief Financial Officer
Sold on a plan indirect
15,693
$11.39
$178.81K
Joshua Pinto
26 Aug 2024
Chief Financial Officer
Sold on a plan indirect
31,642
$11.78
$372.59K
Joshua Pinto
23 Aug 2024
Chief Financial Officer
Sold on a plan indirect
24,169
$11.59
$280.01K
Joshua Pinto
22 Aug 2024
Chief Financial Officer
Sold on a plan indirect
28,496
$11.63
$331.47K
Show all 76 transactions →

What was left out

Form 4 filings counted 101
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 12
Sales on a Rule 10b5-1 plan 16
Sales straight out of an exercise 13
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 97,521,043
History held since 18 Sep 2023